• DOI:10.1210/jc.2015-2580
• Corpus ID: 25439855

Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.

@article{Irani2015VitaminDS,
  title={Vitamin D Supplementation Decreases TGF-$\beta$1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.},
  author={Mohamad Irani and David B. Seifer and Richard V. Grazi and Nitasha Julka and Devika Bhatt and Bharati Kalgi and Sara Irani and Oded Tal and Geralyn M Lambert-Messerlian and Reshef Tal},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2015},
  volume={100 11},
  pages={
          4307-14
        }
}

• M. Irani, D. Seifer, +7 authors R. Tal
• Published 20 October 2015
• Medicine
• The Journal of clinical endocrinology and metabolism

CONTEXT
There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. Vitamin D (VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis.

OBJECTIVE
The objective of the study was to determine the effect of VD supplementation on TGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF-β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations.

DESIGN
This was a prospective, randomized, placebo-controlled trial.

SETTING
The study was conducted at an academic-affiliated medical center.

PARTICIPANTS
Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015.

INTERVENTIONS
Forty-five women received 50 000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for 8 weeks.

MAIN OUTCOMES MEASURES
Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and 2 months after treatment.

RESULTS
The VD level significantly increased and normalized after VD supplementation (16.3 ± 0.9 [SEM] to 43.2 ± 2.4 ng/mL; P < .01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80 ± 9 to 60 ± 6 d; P = .04), Ferriman-Gallwey score (9.8 ± 1.5 to 8.1 ± 1.5; P < .01), triglycerides (138 ± 22 to 117 ± 20 mg/dL; P = .03), and TGF-β1 to sENG ratio (6.7 ± 0.4 to 5.9 ± 0.4; P = .04). In addition, the ΔTGF-β1 to sENG ratio was positively correlated with Δtriglycerides (r = 0.59; P = .03).

CONCLUSIONS
VD supplementation in VD-deficient women with PCOS significantly decreases the bioavailability of TGF-β1, which correlates with an improvement in some abnormal clinical parameters associated with PCOS. This is a novel mechanism that could explain the beneficial effects of VD supplementation in women with PCOS. These findings may support new treatment modalities for PCOS, such as the development of anti-TGF-β drugs.